Core Viewpoint - Guangji Pharmaceutical has experienced a significant surge in stock price, achieving three consecutive daily limit-ups, with a total increase of 33.18% during this period [2] Stock Performance Summary - As of 9:34 AM, the stock price reached 8.55 yuan, with a turnover rate of 8.01% and a trading volume of 27.55 million shares, amounting to a transaction value of 230 million yuan [2] - The stock's limit-up orders totaled 151 million yuan, and the latest total market capitalization of A-shares is 2.965 billion yuan, with a circulating market capitalization of 2.941 billion yuan [2] Trading Data Overview - The stock has been listed on the Dragon and Tiger List due to a cumulative price deviation of 20% over three trading days, with institutional investors net selling 30.09 million yuan while other trading seats collectively net bought 42.08 million yuan [2] - Daily performance data shows fluctuations in trading volume and net capital inflow, with notable increases on October 21 (9.97% increase, 37.44 million yuan net inflow) and October 22 (10.06% increase, 16.51 million yuan net inflow) [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东及实际控制人就相关事项进行 了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要补充、更正之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息。 3、近期公司生产经营情况正常，内外部经营环境未发生重大变化。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 湖北广济药业股份有限公司（以下简称"公司"）（证券简称：广济药业，证券代码：000952）股票交易 连续三个交易日（2025年10月20日、2025年10月21日、2025年10月22日）收盘价格涨幅偏离值累计超过 20%。根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 4、公司及控股股东、实际控制人不存在应披露而未披露的重大事项，或处于筹划阶段的重大事项。 5、股票交易异常波动期间，公司控股股东、实际控制人未发生买卖本公司股票的情形。 三季度报告》。 ...

（文章来源：证券日报） 证券日报网讯 10月22日晚间，广济药业发布公告称，公司股票交易连续三个交易日（2025年10月20 日、2025年10月21日、2025年10月22日）收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动的 情况。经核实，公司前期披露的信息不存在需要补充、更正之处；公司未发现近期公共传媒报道了可能 或已经对本公司股票交易价格产生较大影响的未公开重大信息；近期公司生产经营情况正常，内外部经 营环境未发生重大变化。 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-051 4、公司及控股股东、实际控制人不存在应披露而未披露的重大事项，或处 于筹划阶段的重大事项。 湖北广济药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 湖北广济药业股份有限公司（以下简称"公司"）（证券简称：广济药业， 证券代码：000952）股票交易连续三个交易日（2025 年 10 月 20 日、2025 年 10 月 21 日、2025 年 10 月 22 日）收盘价格涨幅偏离值累计超过 20%。根据《深圳 证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东及 实际控制人就相关事项进行了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要补充、更正之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、近期公司生产经营情况正常，内外部经营环境未发生重大 ...

Core Viewpoint - The pharmaceutical sector has experienced significant stock price increases, with Hendi Pharmaceutical reaching a 20% limit-up, and several other companies also showing substantial gains [1] Group 1: Company Performance - Hendi Pharmaceutical's stock surged by 20%, hitting the daily limit [1] - Duori Pharmaceutical's stock rose by over 13% [1] - Other companies such as Guangji Pharmaceutical, Te Yi Pharmaceutical, Hasan Lian, and Chenxin Pharmaceutical also reached their daily limit [1]

Core Viewpoint - The A-share market continues to see an upward trend in flu-related stocks, driven by rising flu activity and concerns over a potentially severe flu season this year [1] Group 1: Stock Performance - Hendi Pharmaceutical has seen a rise of over 18% - Dori Pharmaceutical has increased by over 11% - Guangji Pharmaceutical and Te Yi Pharmaceutical have hit the 10% daily limit up - Chenxin Pharmaceutical has also increased by over 6% - Notably, Guangji Pharmaceutical has achieved two consecutive limit-up days [1] Group 2: Flu Activity and Expert Insights - The China CDC reported that flu activity in northern provinces is currently low, while southern provinces are experiencing an increase - Overall, respiratory disease incidence is showing a slow upward trend nationwide - Experts indicate that the main flu strain this year is likely to be the H3N2 subtype, which was largely absent last year, leading to lower immunity levels in the population - Many experts believe that this year's flu season may arrive earlier and result in a higher number of infections [1]

Core Insights - The article discusses the first batch of bio-manufacturing landmark products announced by Hubei Province's Economic and Information Technology Department on October 9, highlighting significant advancements in the bio-manufacturing sector [2]. Group 1: Landmark Products - The first batch of landmark bio-manufacturing products includes: - Dongyang Sunshine: Thiocyanate Erythromycin - Tianji Bioenergy: Ultra-clean biodiesel - Bafeng Pharmaceutical: Amino acid raw materials - Xinhua Yang: Feed enzyme preparations - Guangji Pharmaceutical: High-quality riboflavin - China National Pharmaceutical Group: Inactivated vaccine for Porcine Circovirus Type 2 - Aibotai Bio: Research antibodies - Huisheng Biotechnology: Tylosin tartrate - Hite Bio-pharmaceutical: Injectable Epinephrine - Fuxing Biotechnology: Arachidonic acid (ARA) powder [2][3]. Group 2: Product Categories - The products are categorized into different types: - Scale Replacement Type: Thiocyanate Erythromycin, Ultra-clean biodiesel, Research antibodies, Tylosin tartrate - Key Improvement Type: Amino acid raw materials, Feed enzyme preparations, High-quality riboflavin, Arachidonic acid powder - Major Innovation Type: Inactivated vaccine for Porcine Circovirus Type 2, Injectable Epinephrine [3].

Market Overview - The chemical pharmaceutical sector increased by 0.82% on the previous trading day, with Jinshi Yao leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers in Chemical Pharmaceutical Sector - Jinshi Yao (300434) closed at 11.39, up 11.78% with a trading volume of 640,000 shares and a turnover of 714 million yuan [1] - Guangji Pharmaceutical (000952) closed at 7.06, up 9.97% with a trading volume of 215,600 shares and a turnover of 150 million yuan [1] - New Ganjing (920367) closed at 23.21, up 9.02% with a trading volume of less than 37,000 shares and a turnover of 85.7 million yuan [1] - Lingkang Pharmaceutical (603669) closed at 5.97, up 7.37% with a trading volume of 327,700 shares and a turnover of 192 million yuan [1] - Xiangdi Pharmaceutical (301211) closed at 13.12, up 6.84% with a trading volume of 190,800 shares and a turnover of 249 million yuan [1] Top Losers in Chemical Pharmaceutical Sector - Anglikang (002940) closed at 38.92, down 6.58% with a trading volume of 210,700 shares and a turnover of 829 million yuan [2] - Shutaishen (300204) closed at 36.99, down 5.57% with a trading volume of 394,900 shares and a turnover of 1467 million yuan [2] - Yatai Pharmaceutical (002370) closed at 7.00, down 4.76% with a trading volume of 1,532,900 shares and a turnover of 1061 million yuan [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 421 million yuan from institutional investors and 643 million yuan from speculative funds, while retail investors saw a net inflow of 1.063 billion yuan [2][3] - Jinshi Yao (300434) had a net inflow of 98.99 million yuan from institutional investors, while retail investors had a net outflow of 71.82 million yuan [3] - Guangji Pharmaceutical (000952) saw a net inflow of 39.50 million yuan from institutional investors, but a net outflow of 23.01 million yuan from retail investors [3]

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Core Viewpoint - The flu-related stocks experienced a significant surge on October 21, with notable increases in companies such as Te Yi Pharmaceutical, Jinshi Yao, and Hualan Vaccine, driven by rising flu activity in southern China and predictions of an earlier flu season this year [1][4]. Group 1: Stock Performance - Te Yi Pharmaceutical reached a trading limit with a price of 10.27, reflecting a 9.96% increase [2] - Jinshi Yao saw a price increase to 11.73, marking a 15.11% rise [2] - Hualan Vaccine's stock rose to 22.15, showing an 11.87% increase [2] - New Ganjing's stock price increased to 23.72, with a rise of 11.41% [2] - Other companies like Hengdi Pharmaceutical and Xiangrikui also followed the upward trend [1]. Group 2: Flu Activity and Predictions - The China CDC reported an increase in flu activity in southern provinces, indicating a potential early onset of the flu season this year [4] - Experts noted that the predominant flu strain this year is H3N2, differing from last year's H1N1 strain, which may lead to lower immunity levels in the population [5]. Group 3: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with recommendations for individuals to get vaccinated between September and November [8] - The flu vaccine needs to be administered annually due to the rapid mutation of the virus, ensuring protection against the current year's strains [8][9]. - High-risk groups, including children under 5, the elderly, and individuals with chronic health conditions, are advised to prioritize vaccination [12].